Cryptic Terran Licences Advanced CNS Assets From Sanofi
Deal Value Under Wraps
The US biotech has nabbed a couple of Sanofi’s Phase III CNS candidates, its third deal of the year aimed at transforming the neuropsychiatry market.
You may also be interested in...
Sun Pharma Will Take Concert’s Alopecia Drug The Rest Of The Way
Coming up after Lilly’s Olumiant and Pfizer’s ritlecitinib in alopecia areata, deuterated ruxolitinib is said to offer a differentiated profile including patient-reported outcomes data.
Deal Watch: Dragonfly Adds Gilead To Its List Of Big-Name Partners
AbbVie inks collaboration and option deal focused on targeted protein degradation with Plexium. Cend and Calabrius merge in an all-stock transaction.
Dupixent Drives Sanofi Growth Again Amid Pipeline Renewal
The major’s atopic dermatitis blockbuster made more than €1.6bn this quarter, but the firm’s R&D costs are rising as it attempts to add some fresh blood to its stagnating pipeline.